Paper Concludes New CMV Treatments Needed

0 Flares Twitter 0 Facebook 0 LinkedIn 0 Google+ 0 0 Flares ×

HCMV Treatments

“Prominent in the current stage of antiviral drug development are: for the treatment of herpesvirus infections: herpes simplex virus (HSV), cytomegalovirus (CMV), and varicella-zoster virus (VZV), respectively; (vi) the role of a new tenofovir prodrug, tenofovir.” – Medicinal Research Reviews

A paper published in 2013 noted that drugs against the Human Cytomegalovirus (CMV) already in existence have many side effects. Others have not been tested enough, and some that were tested were actually stopped altogether. According to this research, “This makes the area of the therapy of (H) CMV infections largely underserved.” (1)

Why do new safe and effective remedies against CMV infection need to be developed?

Medscape.com says the reason is that “Clinically significant CMV disease (reactivation of previously latent infection or newly acquired infection) frequently develops in patients immunocompromised by HIV infection, solid-organ transplantation, or bone marrow transplantation, as well as in those receiving high-dose steroids, tumor necrosis antagonists, or other immunosuppressing medications for conditions such as systemic lupus erythematosus (SLE), rheumatoid arthritis, Crohn disease, or psoriasis, among others. In patients coinfected with HIV, CMV infection leads to progression to AIDS and eventually death, even in those receiving highly active antiretroviral therapy (HAART).” (2)

Since CMV can cause so many illnesses, and considering the many side effects many current CMV drugs possess, such as Diarrhea, upset stomach, dizziness, drowsiness, unsteadiness, shaking, and even seizures, (3) it is evident that new drugs or remedies must be discovered or developed.

This is especially true, considering that another study showed that use of drugs such as ganciclovir, its oral prodrug valganciclovir, cidofovir, foscavir and fomivirsen is “limited by their toxicity, poor oral bioavailability, modest efficacy, and the development of drug resistance.” (4)

References:

(1) De Clercq E1. “A Cutting-Edge View on the Current State of Antiviral Drug Development.” Med Res Rev. 2013 Mar 11.

(2) MedScape.com – Cytomegalovirus – Practice Essentials – Updated: Apr 7, 2014

(3) WebMD.com – “Ganciclovir Intravenous”

(4) Polansky H, Itzkovitz E. Gene-Eden-VIR Is Antiviral: Results of a Post Marketing Clinical Study. Pharmacology & Pharmacy, 2013, 4, 1-8

 

 

 

 

 

 

Leave a Reply